Intelligence Feed event · Equity · 2026-09-09

    Dentsply Sirona Beats Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY26 Outlook

    Question

    Dentsply Sirona Beats Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY26 Outlook

    Direct answer

    DENTSPLY SIRONA reported second-quarter adjusted earnings of $0.52 per share, surpassing consensus expectations of $0.36 despite a 4.1% year-over-year revenue contraction. Growth was bolstered by a 7.1% sales expansion in its Wellspect Healthcare business line. Management reaffirmed its full-year 2026 financial guidance, anticipating net revenue between $3.5 billion and $3.6 billion with adjusted EPS projected in the $1.40 to $1.50 band, demonstrating operational cost control against equipment demand softness.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Dentsply Sirona Beats Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY26 Outlook”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/dentsply-sirona-beats-q2-eps-at-0-52-vs-0-36-consensus-and-affirms-fy26-outlook-a4be11

    EQUITY
    Dentsply Sirona Beats Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY26 Outlook
    DENTSPLY SIRONA reported second-quarter adjusted earnings of $0.52 per share, surpassing consensus expectations of $0.36 despite a 4.1% year-over-year revenue contraction. Growth was bolstered by a 7.1% sales expansion in its Wellspect Healthcare business line. Management reaffirmed its full-year 2026 financial guidance, anticipating net revenue between $3.5 billion and $3.6 billion with adjusted EPS projected in the $1.40 to $1.50 band, demonstrating operational cost control against equipment demand softness.
    XRAYALGN
    Impact
    67
    SEP 9
    SIG
    85%
    XRAYALGN
    Dentsply Sirona Beats Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY26 Outlook
    DENTSPLY SIRONA reported second-quarter adjusted earnings of $0.52 per share, surpassing consensus expectations of $0.36 despite a 4.1% year-over-year revenue contraction. Growth was bolstered by a 7.1% sales expansion in its Wellspect Healthcare business line. Management reaffirmed its full-year 2026 financial guidance, anticipating net revenue between $3.5 billion and $3.6 billion with adjusted EPS projected in the $1.40 to $1.50 band, demonstrating operational cost control against equipment demand softness.
    → Strong adjusted operating profitability in medical consumables offsets top-line dental equipment declines, stabilizing full-year earnings visibility for XRAY within the $1.40 to $1.50 EPS guidance range.
    Impact
    DENTSPLY SIRONA reported second-quarter adjusted earnings of $0.52 per share, surpassing consensus expectations of $0.36 despite a 4.1% year-over-year revenue contraction. Growth was bolstered by a 7.1% sales expansion in its Wellspect Healthcare business line. Management reaffirmed its full-year 2026 financial guidance, anticipating net revenue between $3.5 billion and $3.6 billion with adjusted EPS projected in the $1.40 to $1.50 band, demonstrating operational cost control against equipment demand softness.
    Affected
    XRAYALGN
    Transmission
    Strong adjusted operating profitability in medical consumables offsets top-line dental equipment declines, stabilizing full-year earnings visibility for XRAY within the $1.40 to $1.50 EPS guidance range.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    XRAYearnings beat and margin resilience against revenue contractionUp1-5dQ2 adjusted EPS of $0.52 beat $0.36 consensus; FY26 guidance reaffirmed at $1.40-$1.50 EPS.
    ALGNpeer dental market demand sentiment read-throughWatch1-4wALGN operates across adjacent dental equipment and consumables end markets.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XRAYUpdisagreed10.72 2026-09-09-2.05%-5.41%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month